Nycomed finds a US partner for asthma drug

Share this article:
Nycomed finds a US partner for asthma drug
Nycomed finds a US partner for asthma drug
The decision by Sepracor to in-license the US marketing rights to inhaled corticosteroid Alvesco caps a four-year commercial and regulatory odyssey for the asthma drug.

Alvesco was approved earlier this month for maintenance and prevention of asthma after a long delay at the FDA, which issued an approvable letter in 2004.

Sepracor expects to launch Alvesco in the second half of the year. As part of the deal, the firm paid Nycomed $150 million up front. It will pay unspecified royalties on sales, plus up to $280 million in milestones. Nycomed is retaining all rights to Alvesco (ciclesonide) outside the US and has partnered with Teijin Pharmaceuticals in Japan, where Alvesco was launched in 2007.

The drug has seen multiple handoffs. Ciclesonide developer Altana Pharma was purchased last year by Nycomed for $6.8 billion, after which Altana launch partner Sanofi-Aventis transferred the Alvesco rights back to Nycomed. That left the privately held Swiss firm, which lacks a US sales force, with no way to bring Alvesco or its cousin Omnaris (a nasal spray formulation of ciclesonide for treating allergic rhinitis approved in 2006) to market.

Sepracor plans to launch Omnaris this spring, adding to a respiratory portfolio that also includes COPD/asthma treatment Xopenex and Brovana, approved for COPD.

It's not out of the woods yet, though, say analysts. “[B]oth the asthma and allergic rhinitis markets are crowded, with significant generic competition, and it is not clear how ciclesonide is differentiated from other corticosteroids,” wrote Friedman Billings Ramsey analyst David Amsellem in an investor note today.

Once-a-day ciclesonide dosing is an advantage over twice-daily inhaled corticosteroids budesonide and fluticasone. But fluticasone, the active ingredient in GlaxoSmithKline's Flonase, went generic in 2006 and accounts for roughly 45% of prescriptions, Amsellem pointed out. And for asthma, GSK's Advair is widely used in the maintenance setting and could become generic in 2011.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...